Roquefort Therapeutics explains the significance of its “very exciting” cancer drug study results

Roquefort Therapeutics’ Vice President – Drug Discovery Graham Robertson speaks to Proactive following the release of new pre-clinical study results.

Robertson tells Proactive that the trial was “the first time that this style of drug has been developed to target midkine”, a substance in the body that plays a role in the development of cancer.

Robertson suggests that the new drug could one day play a role in inhibiting tumour growth in human patients.

#proactiveinvestors #roqueforttherapeutics #oncology #oncotherapy

You might like

© 2022 The Latest StockMarket News and Interviews